Results 21 to 30 of about 8,676,773 (167)

Evaluation of the Effectiveness of the Risk Minimization Measures of Sodium Oxybate in the European Union

Drugs - Real World Outcomes, 2020
Background Sodium oxybate (Xyrem®), approved by the European Medicines Agency (EMA) for narcolepsy with cataplexy, is only available through risk mitigation programs due to potential adverse effects including respiratory and central nervous system ...
Alex Iranzo, Pedro Serralheiro, Jan-Christof Schuller, Anne-Françoise Schlit, Jürgen W. G. Bentz   +4 more
doaj   +1 more source

Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1 [PDF]

, 2018
Narcolepsy type 1 is characterised by an increase in body weight after disease onset, frequently leading to obesity. It was suggested that this weight gain may be counteracted by treatment with sodium oxybate. We here provide longitudinal body mass index
Smolders, I.M., Donjacour, C.E., Wisse P. Meijden, Lammers, Gert Jan, Schinkelshoek, Mink S., Rolf Fronczek, Smolders, Isabelle M, Zwet, E.W. van, Donjacour, Claire E., Meijden, W.P. van der, Donjacour, Claire E H M, Gert Jan Lammers, Erik W. Zwet, van der Meijden, Wisse P, Mink S. Schinkelshoek, Isabelle M. Smolders, Fronczek, Rolf, Fronczek, R., Smolders, Isabelle M., Schinkelshoek, M.S., Lammers, G.J., Schinkelshoek, Mink S, van Zwet, Erik W., van der Meijden, Wisse P., van Zwet, Erik W, Claire E. Donjacour   +25 more
core   +1 more source

Sialidosis type I: How to alleviate disabling myoclonic seizures?-A multicenter analysis of eight cases and review of the literature. [PDF]

Epilepsia Open
Abstract Objective Sialidosis type I (ST‐1) is an autosomal‐recessive, very rare, progressive lysosomal storage disorder caused by pathogenic variants in NEU1. It is clinically characterized by progressive ataxia, myoclonic seizures (MS), bilateral tonic–clonic seizures (BTCS), and distinctive ophthalmological findings.
Gburek-Augustat J, Lee IC, Rubino M, Topçu V, Chavez-Castillo M, Tu SC, Shinawi M, Alfradique-Dunham I, Valtcheva M, Adarmes-Gómez A, Macias-Garcia D, Laura Muñoz-Delgado L, Jesús S, Mir P, Merkenschlager A, Coppola A.   +15 more
europepmc   +2 more sources

Pharmacotherapy of Narcolepsy: Focus on Sodium Oxybate

, 2010
Narcolepsy is a complex disease with multiple symptoms that include excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis. Pharmacologic management of patients with narcolepsy is based on treating these symptoms. Sodium
Sanjeev V. Kothare, Joseph Kaleyias
core   +1 more source

Efficiency of sodium oxybate in episodic cluster headache

, 2013
We report the case of a 60-year-old man suffering from episodic cluster headache treated successfully with sodium oxybate.
Hidalgo, H, Kallweit, U, Uhl, V, Gantenbein, A R, Sándor, P S   +4 more
core   +1 more source

The cost-utility of sodium oxybate as narcolepsy treatment

, 2017
AIMS AND OBJECTIVES: Based on class-I studies, sodium oxybate is regarded as a first-line treatment for both EDS and cataplexy. The cost-effectiveness of sodium oxybate is largely unknown, though.
Kjellberg, J., Jennum, P., Wasling, Pontus,, H. Meinild, Wasling, P, J. Kjellberg, Jennum, P, P. Wasling, K. Bolin, P. Berling, Bolin, Kristian,, Bolin, K, Berling, P, Meinild, H., Meinild, H, P. Jennum, Berling, P., Kjellberg, J   +17 more
core   +1 more source

Sodium oxybate plus nalmefene for the treatment of alcohol use disorder: A case series.

, 2016
The treatment of alcohol use disorder still remains a challenge. The efficacy of the combined pharmacological treatment for alcohol use disorder has been widely investigated with controversial results.
BERNARDI, MAURO, Addolorato, G, D'Amore, Antonio, Maremmani, Angelo G. I., Caputo, F, Caputo, Francesco Maria, Caputo, Fabio, Addolorato, Giovanni, Maremmani, A, D’Amore, A, DOMENICALI, MARCO, Zoli, Giorgio, Maremmani, Icro, Zoli, G   +13 more
core   +1 more source

Symptom Severity and Treatment Satisfaction in Patients with Idiopathic Hypersomnia: The Real World Idiopathic Hypersomnia Outcomes Study (ARISE)

Nature and Science of Sleep, 2023
Logan Douglas Schneider,1 Joanne Stevens,2 Aatif M Husain,3 Diane Ito,4 Douglas S Fuller,5 Phyllis C Zee,6 Wayne Macfadden2 1Stanford University Sleep Medicine Center, Stanford University School of Medicine, Stanford, CA, USA; 2Global Medical Affairs ...
Schneider LD, Stevens J, Husain AM, Ito D, Fuller DS, Zee PC, Macfadden W   +6 more
doaj  

Narcolepsy and rapid eye movement sleep

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Since the first description of narcolepsy at the end of the 19th Century, great progress has been made. The disease is nowadays distinguished as narcolepsy type 1 and type 2. In the 1960s, the discovery of rapid eye movement sleep at sleep onset led to improved understanding of core sleep‐related disease symptoms of the disease (excessive ...
Francesco Biscarini, Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, Yves Dauvilliers   +4 more
wiley   +1 more source

Parasomnias and sleep‐related movement disorders induced by drugs in the adult population: a review about iatrogenic medication effects

Journal of Sleep Research, Volume 34, Issue 2, April 2025.
Summary Parasomnias and sleep‐related movement disorders (SRMD) are major causes of sleep disorders and may be drug induced. The objective of this study was to conduct a systematic review of the literature to examine the association between drug use and the occurrence of parasomnias and SRMD.
Sylvain Dumont, Vanessa Bloch, Agnès Lillo‐Lelouet, Christine Le Beller, Pierre A. Geoffroy, Marc Veyrier   +5 more
wiley   +1 more source